Aaron Wealth Advisors LLC Acquires Shares of 925 Insulet Corporation $PODD

Key Points

• Aaron Wealth Advisors LLC acquired a new position in Insulet Corporation, investing approximately $291,000 for 925 shares during the second quarter.
• Insulet reported $1.17 earnings per share (EPS) for the last quarter, exceeding expectations, and is forecasting a 3.92 EPS** for the current year.
• Analysts have given Insulet a rating of "Moderate Buy" with an average price target of $343.06, reflecting strong confidence in the company's potential growth.

Aaron Wealth Advisors LLC bought a new stake in Insulet Corporation (NASDAQ:PODD - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 925 shares of the medical instruments supplier's stock, valued at approximately $291,000.

A number of other institutional investors have also made changes to their positions in PODD. Financiere des Professionnels Fonds d investissement inc. purchased a new stake in shares of Insulet in the 2nd quarter valued at approximately $543,000. Czech National Bank raised its position in Insulet by 6.8% in the second quarter. Czech National Bank now owns 17,202 shares of the medical instruments supplier's stock valued at $5,405,000 after purchasing an additional 1,091 shares during the period. Paladin Wealth LLC acquired a new position in Insulet during the second quarter worth $566,000. Gradient Investments LLC acquired a new position in Insulet during the second quarter worth $17,429,000. Finally, Kera Capital Partners Inc. purchased a new position in shares of Insulet during the second quarter worth $206,000.

Insider Transactions at Insulet

In related news, SVP Prem Singh sold 687 shares of the company's stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the transaction, the senior vice president directly owned 3,456 shares of the company's stock, valued at $1,200,925.44. This represents a 16.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Laetitia Cousin sold 797 shares of the stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the transaction, the senior vice president owned 3,890 shares in the company, valued at $1,356,870.90. This represents a 17.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.39% of the company's stock.

Insulet Stock Up 1.3%

Shares of PODD traded up $4.28 during midday trading on Monday, reaching $335.12. The stock had a trading volume of 431,486 shares, compared to its average volume of 593,672. The company has a market cap of $23.59 billion, a price-to-earnings ratio of 101.86, a PEG ratio of 2.75 and a beta of 1.36. The company's fifty day simple moving average is $316.00 and its two-hundred day simple moving average is $295.09. Insulet Corporation has a 1-year low of $225.37 and a 1-year high of $353.50. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81.

Insulet (NASDAQ:PODD - Get Free Report) last issued its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, topping analysts' consensus estimates of $0.92 by $0.25. The firm had revenue of $649.10 million during the quarter, compared to the consensus estimate of $612.31 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The company's revenue was up 32.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.55 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Equities research analysts expect that Insulet Corporation will post 3.92 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Piper Sandler boosted their price objective on Insulet from $320.00 to $360.00 and gave the company an "overweight" rating in a report on Tuesday, September 16th. Wall Street Zen upgraded shares of Insulet from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Raymond James Financial reissued an "outperform" rating and issued a $360.00 price objective (up previously from $328.00) on shares of Insulet in a research note on Tuesday, May 27th. Barclays lifted their price objective on shares of Insulet from $266.00 to $300.00 and gave the company an "equal weight" rating in a report on Thursday, August 21st. Finally, Wells Fargo & Company increased their target price on shares of Insulet from $330.00 to $350.00 and gave the stock an "overweight" rating in a report on Friday, August 8th. Sixteen analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $343.06.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.